Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys

Michelle V. Fanucchi, Edward S. Schelegle, Gregory L. Baker, Michael J. Evans, Ruth J McDonald, Laurel J. Gershwin, Eyal Raz, Dallas Melvin Hyde, Charles G. Plopper, Lisa A. Miller

Research output: Contribution to journalArticlepeer-review

68 Scopus citations


To determine whether inhaled immunostimulatory DNA sequence oligonucleotides containing CpG motifs mitigate the pathophysiologic manifestation of the asthmatic phenotype (airways hyperresponsiveness and airways remodeling), rhesus monkeys with experimentally induced allergic airways disease were treated seven times with inhaled immunostimulatory oligonucleotides (or sham) periodically for 33 weeks. Airways hyperresponsiveness was reduced twofold in immunostimulatory DNA sequence-treated compared with sham-treated monkeys. Airways from immunostimulatory oligonucleotide-treated monkeys had thinner reticular basement membranes, fewer mucous cells, fewer eosinophils, and fewer mast cells than sham-treated allergic monkeys. We conclude that inhaled immunostimulatory oligonucleotides can attenuate the magnitude of airway hyperreactivity and airways remodeling produced in nonhuman primates with experimentally induced allergic airways disease.

Original languageEnglish (US)
Pages (from-to)1153-1157
Number of pages5
JournalAmerican Journal of Respiratory and Critical Care Medicine
Issue number11
StatePublished - Dec 1 2004


  • Airway wall alterations
  • Allergic asthma
  • Immunostimulatory DNA sequence oligonucleotides
  • Nonhuman primate

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys'. Together they form a unique fingerprint.

Cite this